Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis

Related Experiment Video

Updated: Dec 6, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.5K

Miaomiao Li1,2, Zeqi Guo1, Dan Zhang3

  • 1Liver Cirrhosis Group, Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly General Hospital of Shenyang Military Area), Shenyang, China.

Gastroenterology Research and Practice
|October 8, 2020
PubMed

Insights

Elevated N-Terminal pro-B-type natriuretic peptide (NT-pro BNP) levels indicate acute decompensating events in liver cirrhosis patients. These findings highlight NT-pro BNP as a key biomarker for monitoring disease progression.

Area of Science:

  • Cardiology
  • Hepatology
  • Biomarker Research

Background:

  • Liver cirrhosis is a significant health concern with complex clinical manifestations.
  • Acute decompensating events in cirrhosis patients often present with multifactorial etiologies.
  • Cardiac biomarkers are increasingly investigated for their role in predicting adverse outcomes in liver disease.

Purpose of the Study:

  • To investigate the association between serum cardiac biomarkers and acute decompensating events in hospitalized cirrhotic patients.
  • To determine the diagnostic utility of NT-pro BNP and hs-cTnT in identifying acute decompensation.
  • To explore correlations between specific cardiac biomarkers and common decompensating events like ascites, gastrointestinal hemorrhage, and ACLF.

Main Methods:

  • Prospective screening of cirrhotic patients hospitalized between January 2016 and March 2019.
  • Measurement of serum cardiac biomarkers: NT-pro BNP, hs-cTnT, CK, CK-MB, and LDH upon admission.
  • Recording of acute decompensating events, including ascites, acute gastrointestinal hemorrhage, and ACLF.

Main Results:

  • NT-pro BNP levels were significantly higher in patients with acute decompensating events (140.75 pg/mL vs. 41.86 pg/mL, P < 0.001) and correlated with ascites, GI hemorrhage, and ACLF.
  • hs-cTnT levels were also elevated in decompensated patients (0.008 ng/mL vs. 0.006 ng/mL, P = 0.007) and correlated with GI hemorrhage.
  • LDH, CK, and CK-MB levels did not show significant differences between decompensated and non-decompensated groups.

Conclusions:

  • Elevated NT-pro BNP levels are strongly associated with acute decompensating events in liver cirrhosis.
  • NT-pro BNP serves as a valuable biomarker for detecting acute decompensation in cirrhotic patients.
  • Further research may elucidate the role of hs-cTnT in specific decompensating events like GI hemorrhage.
Abstract

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.7K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.0K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
636
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
100
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
396
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
118
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
125
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
238